Press "Enter" to skip to content

Nova Mentis and Mycrodose Therapeutics Declare Transdermal Technology Advancement

Nova Mentis Life Science Corp., a biotechnology business focusing on creating innovativ psilocybin-based treatment for neuroinflammatory illnesses as well as Mycrodose Therapeutics. NOVA’s psilocybin-based drug development program has been successfully merged with Mycrodose’s transdermal technology, according to the business focusing on creating innovative drug delivery systems for use with psychedelic chemicals.

Mycrodose Therapeutics’ facilities in San Diego, CA are conducting the first permeation experiments on human skin to demonstrate that NOVA’s medicinal molecule may be effectively administered through human skin utilizing Mycrodose’s transdermal technology. Neuroinflammatory diseases, such as Fragile X Syndrome, the most prevalent genetic cause of Autism Spectrum Disorder, may not require a high dose of psychedelic substance or a huge macrodose quantity of medicine to assist a patient therapeutically, according to the firms.

“This cooperative transdermal delivery method opens the possibility for treating persistent developmental diseases like Fragile X Syndrome without subjecting the child or adult to unpleasant hallucinogenic side effects,” said Will Rascan, CEO and President of NOVA. “A low-dose, or microdose, medication therapy via a transdermal patch is perfect because it can be monitored and changed at home or in the clinic, saving time for our overloaded medical community and lowering medical expenditures for families with impaired children.”

Nova performed four preclinical investigations that confirmed the therapeutic effects of its patented psilocybin-based medication and established a microdose therapeutic threshold for psilocybin that may be employed in future human trials. Nova is the first biotech firm to acquire orphan drug status for psilocybin FXS in the United States and the European Union, which will considerably expedite the business’s journey to medication approval.

Be First to Comment

Leave a Reply

Your email address will not be published. Required fields are marked *